drugset / Trial / NCT07177066

A Study of EDG-15400 in Healthy Adults

NCT07177066 ↗

Phase 1 Recruiting 108 enrolled Edgewise Therapeutics, Inc.
RandomizedSequentialTriple-blindBasic science

Summary

The purposes of this Phase 1 study of EDG-15400 are to: 1. Learn about the safety of EDG-15400 after single and multiple doses in healthy adults 2. Learn about how EDG-15400 is tolerated after single and multiples doses in healthy adults 3. Evaluate the amount of EDG-15400 in the blood and urine after single and multiple doses in healthy adults 4. Evaluate the effect of a meal on the amount of EDG-15400 that is in the blood in healthy adults 5. Evaluate whether the amount of EDG-15400 in the blood is similar for the suspension and tablet forms of EDG-15400 in healthy adults Participants will receive a single or multiple doses of EDG-15400 or a placebo by mouth.

Timeline

Start
2025-08-20
Primary completion
2026-05
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Subject EDG-15400 Unknown — Oral

Indications

No indication recorded.